Management of Asthma: The Current US and European Guidelines

Reddy, Ashwini P.; Gupta, Meera

doi:10.1007/978-1-4614-8603-9_6

Cited by 53 publications

(37 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These treatments typically utilize high-dose CS in combination with a long-acting β 2 -adrenergic receptor agonist along with additional adjunctive treatments, such as those directed against IgE (118). However, clearly, for currently poorly understood reasons, disease symptoms and asthma exacerbations in patients with very severe disease are not adequately managed despite use of these combined therapies.…”

Section: Combination Therapy In Severe Asthmamentioning

confidence: 99%

Current concepts of severe asthma

Ray¹,

Raundhal²,

Oriss³

et al. 2016

Journal of Clinical Investigation

194

175

View full text Add to dashboard Cite

Section: Combination Therapy In Severe Asthmamentioning

confidence: 99%

Current concepts of severe asthma

Ray¹,

Raundhal²,

Oriss³

et al. 2016

Journal of Clinical Investigation

194

175

View full text Add to dashboard Cite

“…The objective of asthma management guidelines is to improve the implementation of current knowledge into daily clinical practice by establishing a consensus of scientific practices for the management of asthma. Initial guidelines were based on consensus of expert opinion but advances in asthma research has led to the development of evidence-based guidelines and a major paradigm shift to control-based asthma management [234].…”

Section: Ait In Asthma: Clinical Guidelinesmentioning

confidence: 99%

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Domínguez‐Ortega

Delgado

Blanco

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Asthma is frequently associated with atopy, characterized by the production of specific immunoglobulin E in response to environmental allergens. Currently, two types of allergen immunotherapy (AIT) are used in clinical practice: subcutaneous and sublingual immunotherapy, both accepted as key components of the therapeutic repertoire for allergic rhinitis and conjunctivitis. However, their role in asthma remains controversial. The present document is aimed at providing the clinicians with a review of the evidence on the use of AIT in asthma, focusing on the most relevant aspects of its mechanism of action, its efficacy, and existing data on safety, tolerability, and cost-effectivity, both in pediatric and adult populations. A systematic search of MEDLINE, Cochrane, and Clinical Trials databases from 2000 to April of 2016 was carried out by a panel of experts from the Spanish Allergy and Clinical Immunology Scientific Society. Relevant studies prior to the year 2000 included in ulterior systematic reviews were also considered. More than 4000 articles were identified during the search and 241 were selected to retrieve available evidence on AIT, which was graded according to the Oxford classification. All the group members reviewed the resulting text until the final version reached the consensual agreement. A summary of recommendations on the more relevant topics are proposed. The role of AIT as a valuable therapeutic strategy for prevention of exacerbation and progressive decline in lung function is highlighted. Future research should include specific tools for asthma evaluation when assessing AIT effectiveness in asthmatic patients. ResumenEl asma se asocia frecuentemente con alergia, entendida ésta como la producción de IgE específica frente a alérgenos ambientales. Actualmente, existen dos tipos de inmunoterapia específica con alérgenos (ITE) para la práctica clínica habitual: subcutánea y sublingual, ambas indicadas en el tratamiento de la rinitis y la conjuntivitis alérgicas. Sin embargo, su papel en el asma resulta todavía controvertido. Dominguez-Ortega J, et al.

show abstract

“…Based on the findings of the present study, it is also possible that COPD patients with multiple trigger factors may have asthma-COPD overlap syndrome, which has been associated with increased illness severity and healthcare utilisation. (7,35,36) In other words, knowledge of trigger factors may help to identify this important clinical phenotype.…”

Section: Discussionmentioning

confidence: 99%

Trigger factors in asthma and chronic obstructive pulmonary disease: a single-centre cross-sectional survey

See¹,

Phua²,

Lim³

2016

smedj

View full text Add to dashboard Cite

INTRODUCTIONThe presence of trigger factors may help to distinguish asthma from chronic obstructive pulmonary disease (COPD). Knowing and avoiding trigger factors for both asthma and COPD can facilitate the design of comprehensive management programmes that can aid disease control. This study aimed to describe the relative frequency and range of various trigger factors in asthma and COPD. METHODSWe conducted a telephone-based survey involving asthma and COPD patients on follow-up at a university hospital in Singapore.RESULTS A total of 779 asthma patients and 129 COPD patients participated in this study. Among these patients, 93.8% of those with asthma and 42.6% of those with COPD had trigger factors (p < 0.001). The median number of trigger factors was greater among asthma patients than among those with COPD (3 vs. 0, p < 0.001). Trigger factors found to be significantly more prevalent among asthma patients compared to those with COPD include tobacco smoke, alcohol, upper respiratory tract infections, incense smoke, perfume, laughter, a dusty environment, air-conditioning, heavy rain, heavy traffic fumes, citrus fruits, gastro-oesophageal reflux, household pets, flowers/pollen, medications and psychological triggers. Trigger factors that were not previously described, such as bathing, fatigue, insufficient sleep, crowded places and overeating, were also reported. CONCLUSIONTrigger factors, although found in both groups of patients, were more common among asthma patients.Knowledge of these trigger factors may be useful in distinguishing between the two diseases and optimising disease management.

show abstract

Management of Asthma: The Current US and European Guidelines

Cited by 53 publications

References 111 publications

Current concepts of severe asthma

Current concepts of severe asthma

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence

Trigger factors in asthma and chronic obstructive pulmonary disease: a single-centre cross-sectional survey

Contact Info

Product

Resources

About